Lead Product(s) : Dalcetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Québec government
Deal Size : $80.0 million
Deal Type : Series D Financing
Details :
Product Name : DAL-302
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 13, 2023
Lead Product(s) : Dalcetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Québec government
Deal Size : $80.0 million
Deal Type : Series D Financing
Lead Product(s) : Dalcetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : DAL-301
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : Dalcetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalcetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DalCor Announces Dal-GenE Trial Continues with Final Data Expected in the First Half of 2021
Details :
Product Name : DAL-301
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Dalcetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable